A5110852714- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Photonic and Optical Devices
- Advanced Fiber Laser Technologies
- Plasmonic and Surface Plasmon Research
- Colorectal Cancer Treatments and Studies
- Perovskite Materials and Applications
- Advanced Fiber Optic Sensors
- Metamaterials and Metasurfaces Applications
- Solid State Laser Technologies
- Cancer Genomics and Diagnostics
- Ga2O3 and related materials
- Laser-Matter Interactions and Applications
- Advanced Antenna and Metasurface Technologies
- 2D Materials and Applications
- GaN-based semiconductor devices and materials
- Cholangiocarcinoma and Gallbladder Cancer Studies
- ZnO doping and properties
- DNA Repair Mechanisms
- Transition Metal Oxide Nanomaterials
- Gas Sensing Nanomaterials and Sensors
- Gold and Silver Nanoparticles Synthesis and Applications
- Advanced Breast Cancer Therapies
Nanjing University of Information Science and Technology
2016-2025
Fudan University Shanghai Cancer Center
2015-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2024
Nanjing University of Posts and Telecommunications
2024
National Clinical Research
2023
Gansu Provincial Hospital
2023
Shandong University
2021-2023
Qilu Hospital of Shandong University
2021-2023
Shanghai Medical College of Fudan University
2014-2021
Fudan University
2007-2020
IntroductionData on immuno-oncology agents in Chinese patients are limited despite a need for new therapies. We evaluated the efficacy and safety of nivolumab predominantly patient population with previously treated NSCLC.MethodsCheckMate 078 was randomized, open-label, phase III clinical trial from China, Russia, Singapore squamous or nonsquamous NSCLC that had progressed during/after platinum-based doublet chemotherapy (ClinicalTrials.gov: NCT02613507). Patients EGFR/ALK alterations were...
Abstract Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of receptor tyrosine kinase. ARROW ( NCT03037385 , ongoing) was designed to evaluate pralsetinib efficacy and safety patients with advanced -altered solid tumors. Twenty-nine 12 different fusion–positive tumor types, excluding non-small-cell lung cancer thyroid cancer, who had previously received or were not candidates for standard therapies, enrolled. The most common fusion partners 23...
Most infrared and visible image fusion algorithms demonstrate satisfactory performance under normal lighting conditions, but often perform poorly in low-light environments because the texture details images are barely dark. To resolve this issue, we have proposed A novel network based on enhancement progressive aware for – (EPAFusion). The EPAFusion efficiently brightens while fusing complementary information from two modalities. Specifically, design a degraded illumination disentangled...
Although lidar is a powerful active remote sensing technology, echo signals are easily contaminated by noise, particularly in strong background light, which severely affects the retrieval accuracy and effective detection range of system. In this study, coupled variational mode decomposition (VMD) whale optimization algorithm (WOA) for noise reduction proposed demonstrated completely. The combination optimal VMD parameters number K quadratic penalty α was obtained using WOA critical acquiring...
In the phase 3 CheckMate 078 study, nivolumab showed significant overall survival (OS) benefit and superior tolerability versus docetaxel in a predominantly Chinese patient population with non-small cell lung cancer (NSCLC). However, data on long-term outcomes immunotherapy Asian patients are limited. We report 2-year efficacy safety data.Patients advanced/metastatic NSCLC disease progression after platinum-doublet chemotherapy were randomized 2:1 to (3 mg/kg every 2 weeks; n = 338) or (75...
Abstract Currently approved HER2-targeting antibody-drug conjugates (ADCs) for HER2-positive breast cancer (BC) are associated with safety concerns. In this multicenter, single-arm, dose-escalation (phase 1a) and dose-expansion 1b) phase 1 trial (NCT03944499), patients HER2-expressing advanced solid tumors received FS-1502 (an anti-HER2 ADC) a 3 + design in 1a; metastatic BC at the recommended 2 dose (RP2D) 1b. The primary end points were dose-limiting toxicities (DLTs), maximum tolerated...
Ad5, adenovirus type 5; CNE, human nasopharyngeal carcinoma cell line; DLT, dose- limiting toxicity; GM-CSF, granulocyte-macrophage colony-stimulating factor; HNC, head and neck cancer; HRP,horseradish peroxidase; hTERT, telomerase reverse transcriptase; IL, interleukin; mtelo, modified promoter; MTD, maximum- tolerated dose; NCI-CTC, National Cancer Institute Common Toxicity Criteria; PCR, polymerase chain reaction; SDS-PAGE,sodium dodecyl sulphate polyacrylamide gel electrophoresis; SCHNC,...
// Chen Lin 1, * , Shanshan Wang Weiwei Xie 1 Rongliang Zheng 2 Yu Gan 3 Jianhua Chang Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, P.R. China Nuclear Medicine, Sun Yat-Sen Guangzhou, 510000, State Key Laboratory Oncogenes and Related Genes, Institute, Renji Hospital, Jiao Tong School These authors contributed equally to this work Correspondence to: Chang, email: changjianhua@163.com Gan, ganyu@shSCI.org Keywords: apatinib, KIF5B-RET, invasion...
MicroRNAs play a critical role in chemoresistance and are implicated various biological pathological processes of cells. The objective the present study was to explore miR‑133b its mechanism regulation cisplatin resistance tumor progression cisplatin‑resistant non‑small cell lung cancer (NSCLC) Reverse transcription‑quantitative polymerase chain reaction western blot assays lines A549/DPP H1299/DDP displayed reduced expression increased glutathione-S-transferase P1 (GSTP1) resistant cells...
Abstract All inorganic perovskite quantum dots (ABX 3 , A = Cs, B Pb, X Cl, Br, or I) are potential candidates for wide‐color‐gamut display applications. High‐efficiency green and red dot (PeQD) light‐emitting diodes (LEDs) have been achieved, however, development of blue‐emitting devices, especially those with the relatively short wavelengths (<470 nm) meeting National Television System Committee blue standard, lag largely behind, mainly due to poor film quality, low photoluminescence...
IntroductionLorlatinib was found to have activity in ALK-positive NSCLC a global phase 1 and 2 study. We report an ongoing study Chinese patients with advanced or metastatic NSCLC.MethodsOpen-label, dual-cohort (NCT03909971); had progressive disease after ALK tyrosine kinase inhibitor treatment (cohort 1: previous crizotinib; cohort 2: one other than crizotinib [±prior crizotinib]), more equal unirradiated extracranial target lesion, Eastern Cooperative Oncology Group performance status of 0...
Pralsetinib is a potent, selective RET inhibitor targeting oncogenic alterations. As part of the global, phase 1/2 ARROW trial (NCT03037385), efficacy and safety pralsetinib in Chinese patients with advanced fusion-positive non-small cell lung cancer (NSCLC) were evaluated.Adult advanced, NSCLC or without prior platinum-based chemotherapy enrolled into two cohorts receiving 400-mg once-daily oral pralsetinib. Primary end points objective response rates assessed by blinded independent central...